This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

This medicinal product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.

Unlock the IQIRVO effect

Primary Biliary Cholangitis (PBC) Video
02:17

The first PPAR agonist licensed as an add on to UDCA, helping you to achieve your treatment goals.*1–5 Watch this video to learn more about IQIRVO’s efficacy.

Footnote
*IQIRVO + UDCA met the primary endpoint of cholestasis response, defined as by ALP <1.67 x ULN, and ALP decrease ≥15% and TB ≤ULN. Reduction in ALP and bilirubin is predictive of long-term outcomes.1–5

References

  1. IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024
  2. Lammers WJ et al. Gastroenterology. 2014;147(6):1338–1349.
  3. Corpechot C et al. Clin Res Hepatol Gastroenterol. 2022;46(1):101770.
  4. de Veer RC et al. Aliment Pharmacol Ther. 2022;56(9):1408–1418.
  5. Murillo Perez CF et al. Am J Gastroenterol. 2020;115(7):1066–1074.

IQV-UK-000155 | November 2024

Explore more Primary Biliary Cholangitis (PBC) Resources

Explore more Primary Biliary Cholangitis (PBC) Resources

Browse